Gilead Sciences (NASDAQ:GILD) Given New $156.00 Price Target at Citigroup

Gilead Sciences (NASDAQ:GILD) had its price objective increased by Citigroup from $140.00 to $156.00 in a report issued on Tuesday, Marketbeat Ratings reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on GILD. Mizuho upped their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday. Daiwa Capital Markets lifted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Truist Financial initiated coverage on Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 price target for the company. Finally, Morgan Stanley lowered their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $135.36.

Gilead Sciences Trading Up 2.3%

Shares of NASDAQ:GILD opened at $140.97 on Tuesday. Gilead Sciences has a 12-month low of $93.37 and a 12-month high of $141.71. The business has a 50 day moving average of $124.53 and a 200-day moving average of $119.10. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market cap of $174.90 billion, a PE ratio of 21.86, a P/E/G ratio of 0.72 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 247,397 shares of company stock valued at $31,986,612. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Norges Bank bought a new stake in Gilead Sciences during the 2nd quarter worth $2,150,268,000. Ameriprise Financial Inc. boosted its stake in shares of Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the last quarter. Invesco Ltd. increased its stake in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after buying an additional 2,169,266 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple major banks raised price targets and kept bullish ratings, increasing investor conviction that upside remains (Citigroup to $156, UBS to $155, BMO to $150, Truist to $145). Analysts cited in these notes are maintaining buy/outperform views, which supports demand for GILD. Citigroup price‑target note UBS/Truist coverage BMO note
• Positive Sentiment: Press reports note GILD reached a new 1‑year high on the analyst upgrade momentum — a technical trigger that can attract momentum buyers and ETFs. AmericanBankingNews article
• Neutral Sentiment: Company fundamentals and guidance remain supportive: Gilead’s most recent quarter beat EPS and revenue expectations and management set FY2025 EPS guidance (8.05–8.25), which underpins analyst optimism but is not new today. (See analyst consensus and company metrics for context.) MarketBeat company summary
• Negative Sentiment: GILD’s CEO, Daniel Patrick O’Day, sold 115,640 shares (avg $135) in a disclosed transaction — a large insider sale that may prompt concern or profit‑taking among some investors despite his remaining sizeable stake. The SEC filing and trade detail are public. SEC Form 4 (insider sale) InsiderTrades report

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.